Furmonertinib, a third-generation EGFR-TKI targeted therapeutic agent, should be administered strictly under medical supervision. Particular attention should be paid to dosage adjustment, adverse reaction monitoring, and drug-drug interactions. This medication is primarily indicated for the treatment of epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). Dosing should be individualized based on the patient's clinical condition and tolerability, and self-adjustment of dosage or premature discontinuation is strictly prohibited.
Medication Administration Guidelines
Strict Adherence to Medical Instructions
The daily dosing time and dosage must be consistent. The recommended standard dose is 80 mg (one tablet) once daily. Administration may occur either on an empty stomach or with food, but a consistent regimen should be maintained. If a dose is missed, it may be taken if the next scheduled dose is more than 10 hours away; otherwise, the missed dose should be skipped.
Prohibition of Unauthorized Modifications
In the event of adverse reactions (e.g., rash, diarrhea), patients must consult their physician for evaluation. Self-discontinuation or dose reduction is strictly forbidden, as it may compromise therapeutic efficacy and accelerate the development of drug resistance.
Management of Adverse Reactions
Common Adverse Reactions
Skin Reactions (occurring in 60%–70% of patients)
Manifestations include skin dryness, rash, and paronychia. Symptomatic management may involve the topical application of moisturizers or antibiotic ointments.
Diarrhea (occurring in 20%–30% of patients)
Mild cases can be managed with smectite powder (montmorillonite). Medical attention should be sought promptly if diarrhea persists or worsens.
Oral Mucositis
Patients should avoid irritating foods and may use Kangfuxin Solution for mouth rinsing as an adjunctive measure.
Severe Adverse Reactions
Interstitial Lung Disease (rare but high-risk)
Immediate drug discontinuation and emergency medical care are required if symptoms such as sudden onset dyspnea and fever occur.
Cardiac Toxicity (QT interval prolongation)
Regular electrocardiographic monitoring is recommended, especially for patients with pre-existing cardiac conditions.
Contraindications and Drug Interactions
Contraindicated Populations
Patients with known hypersensitivity to any ingredient of furmonertinib.
Pregnant and lactating women (effective contraceptive measures must be implemented during treatment).
Patients with severe hepatic or renal impairment (dosage adjustment is necessary under medical supervision).
Drug-Drug Interactions
Concomitant use with strong CYP3A4 inducers (e.g., rifampicin, phenytoin) or strong CYP3A4 inhibitors (e.g., clarithromycin) should be avoided.
Proton pump inhibitors (e.g., omeprazole) should be used with caution, as they may reduce the bioavailability and therapeutic efficacy of furmonertinib. A dosing interval of at least 2 hours is recommended if co-administration cannot be avoided.
Follow-Up and Monitoring
Regular Re-evaluations
Patients should undergo follow-up assessments every 2–3 months, including chest computed tomography (CT), complete blood count, and hepatic and renal function tests. Prompt brain magnetic resonance imaging (MRI) is indicated if symptoms suggestive of brain metastasis (e.g., headache, vomiting) develop.
Genetic Testing: Re-testing for EGFR gene mutations is recommended upon disease progression to guide the selection of subsequent therapeutic strategies.
